Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 9/20 | 0.53 |
| ▸ | ITGB6 | P18564 | 8/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.53 |
| ▸ | ITGB5 | P18084 | 7/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24341476 | 0.89 | ITGAV (0.52) | ITGAVITGB6ITGB3ITGB5ITGA2B | |
| SCHEMBL26033637 | 0.87 | ITGAV (0.52) | ITGAVITGB6ITGB3ITGB5ITGA2B | |
| SCHEMBL26031769 | 0.87 | ITGAV (0.50) | ITGAVITGB6ITGB3ITGB5ITGA2B | |
| SCHEMBL7039474 | 0.86 | ITGAV (0.57) | ITGAVITGB6ITGB3ITGB5ITGA2B | |
| SCHEMBL30446650 | 0.86 | ITGAV (0.54) | ITGAVITGB6ITGB3ITGB5ITGA2B | |
| SCHEMBL6589410 | 0.85 | ITGB3 (0.53) | ITGAVITGB6ITGB3ITGB5ITGA2B | |
| SCHEMBL26033788 | 0.84 | ITGAV (0.50) | ITGAVITGB6ITGB3ITGB5ITGA2B | |
| SCHEMBL26033791 | 0.83 | ITGAV (0.49) | ITGAVITGB6ITGB3ITGB5ITGA2B | |
| SCHEMBL28804474 | 0.82 | ITGAV (0.56) | ITGAVITGB6ITGB3ITGB5ITGA2B | |
| SCHEMBL5856027 | 0.81 | ITGB3 (0.58) | ITGAVITGB6ITGB3ITGB5ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | ITGAV 836/4885ITGB6 874/4885ITGB3 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.